Fennec Pharmaceuticals: Funding, Investors & Team (Aug 2026)
Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo. Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.
Fennec Pharmaceuticals has raised $70.0M across 2 funding rounds on record, the most recent an undisclosed round of $25.0M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Fennec Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Fennec Pharmaceuticals Funding Rounds
Fennec Pharmaceuticals raised $45.0M in a Post-IPO Equity announced in Aug 2022.
3 months later, an undisclosed round of $25.0M was announced in Nov 2022.
Fennec Pharmaceuticals Founders and Leadership Team
Contact details for the Fennec Pharmaceuticals team: 1 of 1 has an email address on file.
Start 14-day free trial →Fennec Pharmaceuticals Funding Compared to Other Biotechnology Startups
Fennec Pharmaceuticals' latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Fennec Pharmaceuticals in Biotechnology and Durham
Companies Similar to Fennec Pharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Fennec Pharmaceuticals Funding FAQs
What does Fennec Pharmaceuticals do?
Fennec Pharmaceuticals Inc. (TSX: FRX, OTC: Interim ADHXD, Final FENCF (October 2, 2014), is a clinical-stage biotechnology company developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. STS is being investigated in two pediatric Phase III studies to evaluate the reduction of ototoxicity and impact on survival. Originating in Saharan North Africa, the fennec fox is the smallest of the foxes and uniquely adapted to high temperatures and low water environments. It has distinctively large ears which dissipate heat and provide a very sensitive hearing. These qualities of adaptability and resourcefulness led us to adopt the fox with the big ears as our new name and logo. Children undergoing chemotherapy are going through an extraordinarily challenging time and the loss of hearing only compounds the difficulty. Fennec Pharma, named after that resourceful and determined fennec fox hopes that STS will allow these children to keep their hearing and prevent permanent disability. As the company refocuses on this mission, it seemed appropriate to adopt the fox with the big ears as our new name and logo.
How much funding has Fennec Pharmaceuticals raised?
Fennec Pharmaceuticals has raised $70.0M across 2 rounds on record. The most recent is an undisclosed round of $25.0M announced in Nov 2022.
When did Fennec Pharmaceuticals last raise funding?
Fennec Pharmaceuticals' most recent funding round on record is an undisclosed round of $25.0M, announced in Nov 2022.
Who is the CEO of Fennec Pharmaceuticals?
Rostislav Raykov is listed as CEO at Fennec Pharmaceuticals.
Where is Fennec Pharmaceuticals headquartered?
Fennec Pharmaceuticals is based in Durham, North Carolina, United States.
How many employees does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals is in the 11-50 employee band.
How does Fennec Pharmaceuticals' funding compare to other Biotechnology startups?
Fennec Pharmaceuticals' latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Fennec Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Fennec Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.